Investigational drug · Phase 3
SHPL-49
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Ischemic Stroke.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SHPL-49"
First trial start
2025
Dec 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHPL-49", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Ischemic Stroke
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SHPL-49" as an intervention, largest first.
- Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic StrokePivotal-lookingRecruiting
Shanghai Hutchison Pharmaceuticals LimitedIndustry
NCT07241520 · 1,096 participants (planned) · Start Dec 8, 2025 · Primary completion Jun 30, 2027
Drug: SHPL-49 Injection; Placebo Injection · For: Acute Ischemic Stroke
Sites: Linfen, China
- Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic StrokePivotal-lookingCompleted
Shanghai Hutchison Pharmaceuticals LimitedIndustry
NCT06202378 · 270 participants · Start Dec 29, 2023 · Primary completion Nov 26, 2024
Drug: 3 ampoules of SHPL-49 Injection; 6 ampoules of SHPL-49 Injection and 1 more · For: Acute Ischemic Stroke
Sites: Beijing, China; Shaoguan, China; Hengshui, China · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Salidroside derivative SHPL-49 enhances synaptic remodeling in BCCAO rats via the CDK5/p35/p25 signaling pathway.
Zhang P, Guo H, Shen Y, et al. · Front Pharmacol 2026
- Salidroside derivative SHPL-49 accelerates cutaneous wound healing in diabetic mice by modulating macrophage-mediated TGF-β1/Smad2/3 signaling pathway.
Wang F, Ma Z, Latif A, et al. · Toxicol Appl Pharmacol 2026
- Salidroside Derivative SHPL-49 Exerts Anti-Neuroinflammatory Effects by Modulating Excessive Autophagy in Microglia.
Zheng Z, Wang R, Zhao Y, et al. · Cells 2025
- Microglia-mediated endothelial protection: the role of SHPL-49 in ischemic stroke.
Zhao Y, Zhang P, Zhang J · Biomed Pharmacother 2024
- Salidroside derivative SHPL-49 attenuates glutamate excitotoxicity in acute ischemic stroke via promoting NR2A-CAMKࡱα-Akt /CREB pathway.
Xie D, Zhang P, You S, et al. · Phytomedicine 2024
- First-in-human study to assess the safety, tolerability, and pharmacokinetics of intravenous SHPL-49 following single- and multiple-ascending-dose administration in healthy adults.
Li S, Yang C, Wang W, et al. · J Pharm Biomed Anal 2024
Also in development for Acute Ischemic Stroke
- TAK-755rADAMTS13, recombinant ADAMTS13Phase 33 trials
Takeda · Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
- SovateltideIRL-1620, PMZ-1620Phase 32 trials
Pharmazz, Inc. · Traumatic Brain Injury, Acute Ischemic Stroke, Cerebral Stroke
- JX10Phase 31 trial
Corxel Pharmaceuticals · Acute Ischemic Stroke
- LT3001Phase 23 trials
Lumosa Therapeutics Co., Ltd. · Acute Ischemic Stroke
- LT3001 DrugPhase 22 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Acute Ischemic Stroke
- B2065Phase 21 trial
Tasly Pharmaceutical Group Co., Ltd · Acute Ischemic Stroke
- BB-031DTRI-031Phase 21 trial
Basking Biosciences, Inc. · Acute Ischemic Stroke
- HRS-4029Phase 21 trial
Beijing Suncadia Pharmaceuticals Co., Ltd · Acute Ischemic Stroke
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.